반응형

Clinical 5

[Emergo, UL] EU Update: Medical Device Regulator MDCG Releases New Guidance on Safety Reporting for IVD Clinical Performance Studies

On April 15, 2024, the Medical Device Coordination Group (MDCG) released a new guidance document; MDCG 2024-4 Safety Reporting in Clinical Performance Studies of in Vitro Diagnostic (IVD) under the EU IVD Regulation (2017/746, IVDR). The guidance provides an in-depth look at safety reporting requirements for IVD performance studies under the IVDR. It introduces a tabular performance study Summar..

뉴스 보고서 2024.05.28

[Emergo, UL] Second Report on the European Clinical Evaluation Consultation Procedure (CECP)

The European Commission (EC) published its second annual overview concerning medical devices subject to the Clinical Evaluation Consultation Procedure (CECP) (Article 54) of the Medical Devices Regulation (MDR) (EU) 2017/745. This is an update to the first CECP report (April 2021-June 2022). The current report summarizes activities of expert panels to the CECP from July 2022 through June 2023. C..

뉴스 보고서 2024.05.02

[Emergo, UL] EU Update: New Guidance on Clinical Investigation Investigators Brochures

What is an investigator’s brochure? The investigator’s brochure (IB) is referenced in the European Medical Devices Regulation (2017/745, MDR). However, those unfamiliar with the term IB will find it defined in Annex XV, Chapter II, Section 2. In the interest of completeness, there is a catch-all expectation in MDR Article 62 on clinical investigations. MDR Article 62(4)(m) states “the requiremen..

뉴스 보고서 2024.05.01

[CE] MDCG 2023-7 Guidance on exemptions from the requirements to perform clinical investigations pursuant to Article 61(4)~(6)

[Introduction] Article 61(4) of Regulation (EU) 2017/745 on medical devices (MDR) requires clinical investigations to be performed for implantable and class III devices, except in four specific cases as outlined in: CASE 1) indents 1-3 of Article 61(4); CASE 2) Article 61(6)(a); CASE 3) Article 61(6)(b); CASE 4) Article 61(5). These four cases which are exempted from the requirement to perform c..

유럽 MDR, IVDR 2023.12.27

[FDA voices] Increasing options in clinical research to facilitate medical product development

Earlier this month I wrote about the importance of clinical trial transparency and the FDA’s oversight. Today, I’d like to catch up with you about another critical component of FDA’s oversight of clinical studies: our work to harmonize clinical research regulations and to facilitate the development of medical products to benefit public health. Modernizing Clinical Research Oversight Efficient, w..

미국 FDA 2023.12.24
반응형